|Bid||307.30 x 100|
|Ask||318.20 x 100|
|Day's range||310.18 - 316.00|
|52-week range||244.28 - 348.84|
|PE ratio (TTM)||20.60|
|Earnings date||24 Oct 2017 - 30 Oct 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||359.00|
Everyone has heard the talk. Pfizer (PFE) is getting ready to make a deal. the skinny on Wall Street is that the U.S. pharmaceutical giant has its eyes set on rival Bristol-Myers Squibb (BMY) and its immuno-oncology ...
A Relative Strength Rating upgrade for Biogen shows improving technical performance. Will it continue?
Ionis Pharmaceuticals (IONS) earned $50 million in milestone payments from Biogen. Spinraza had a strong third quarter as announced by Biogen in its earnings results.
Despite robust demand trends in the US, launches in new countries are expected to drive revenue growth of Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza in 4Q17.
In 3Q17, Biogen (BIIB) and Ionis Pharmaceuticals' (IONS) Spinraza reported sales worth $73 million from international markets.
Biogen (BIIB) and Ionis Pharmaceuticals’ (IONS) Spinraza has been witnessing improvement in infrastructure and payer access for spinal muscular atrophy (or SMA) patients in the US in 2017.
In 1H17, Ionis Pharmaceuticals (IONS) recorded revenues of about $27.6 million related to royalty income received from Biogen from Spinraza sales.
In its 2Q17 earnings conference call, Ionis Pharmaceuticals (IONS) raised its guidance for 2017 pro forma operating income.
In October 2017, Biogen (BIIB) and Eisai expanded their existing agreement on the joint development and commercialization of Alzheimer’s disease therapies under investigation. According to the terms of ...
In 3Q17, Biogen’s (BIIB) biosimilars generated revenue of ~$101 million, compared with $31 million in 3Q16. They witnessed 11% growth QoQ (quarter-over-quarter). In 3Q17, Benepali generated revenue of ...
In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ...
In 3Q17, Biogen’s (BIIB) Tecfidera generated revenue of ~$1.1 billion, which reflected 3% growth YoY (year-over-year) and a 4% fall QoQ (quarter-over-quarter). In 3Q17, Tecfidera contributed to ~40.8% ...
The third quarter reporting cycle is witnessing accelerating revenues and positive revisions trend for Q4. Let's see if some of the other leading players AbbVie and Merck follow suit.
Jim Cramer shared his take on callers' favorite stocks at lightning speed, including a well-known name in grocery.
Key highlights include Biogen's (BIIB) Q3 results and regulatory news from companies like Gilead and Alexion.